World's Best Scientists 2026 revealed!
Akira Nakagawara

Akira Nakagawara

D-Index & Metrics

Molecular Biology

D-Index
87
Citations
24678
World Ranking
806
National Ranking
62

Akira Nakagawara publication distribution in Molecular Biology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Molecular Biology in 2026. The highlighted bar marks where Akira Nakagawara sits on this spectrum.

47–56 publications: 7 scientists 57–66 publications: 17 scientists 67–76 publications: 65 scientists 77–86 publications: 90 scientists 87–96 publications: 125 scientists 97–106 publications: 131 scientists 107–116 publications: 162 scientists 117–126 publications: 177 scientists 127–136 publications: 158 scientists 137–146 publications: 158 scientists 147–156 publications: 146 scientists 157–166 publications: 159 scientists 167–176 publications: 131 scientists 177–186 publications: 110 scientists 187–196 publications: 112 scientists 197–206 publications: 100 scientists 207–216 publications: 89 scientists 217–226 publications: 98 scientists 227–236 publications: 74 scientists 237–246 publications: 72 scientists 247–256 publications: 63 scientists 257–266 publications: 53 scientists 267–276 publications: 54 scientists 277–286 publications: 49 scientists 287–296 publications: 52 scientists 297–306 publications: 43 scientists 307–316 publications: 46 scientists 317–326 publications: 41 scientists 327–336 publications: 42 scientists 337–346 publications: 31 scientists 347–356 publications: 28 scientists 357–366 publications: 29 scientists 367–376 publications: 26 scientists 377–386 publications: 24 scientists 387–396 publications: 24 scientists 397–406 publications: 14 scientists 407–416 publications: 13 scientists 417–426 publications: 20 scientists 427–436 publications: 12 scientists 437–446 publications: 20 scientists 447–456 publications: 11 scientists 457–466 publications: 10 scientists 467–476 publications: 14 scientists 477–486 publications: 14 scientists 487–496 publications: 10 scientists 497–506 publications: 13 scientists 507–516 publications: 13 scientists 517–526 publications: 2 scientists 527–536 publications: 4 scientists 537–546 publications: 6 scientists 547–556 publications: 8 scientists 557–563 publications: 6 scientists 564+ publications: 100 scientists
47 publications 564+

This scientist: 366 publications — 88th percentile

88% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 564 publications or more.

Akira Nakagawara D-index placement in Molecular Biology in 2026

The chart shows the D-index (discipline H-index) distribution of Molecular Biology scientists ranked by Research.com in 2026. The highlighted bar marks where Akira Nakagawara sits on this spectrum.

40–41 D-Index: 36 scientists 42–43 D-Index: 101 scientists 44–45 D-Index: 115 scientists 46–47 D-Index: 121 scientists 48–49 D-Index: 118 scientists 50–51 D-Index: 130 scientists 52–53 D-Index: 106 scientists 54–55 D-Index: 116 scientists 56–57 D-Index: 113 scientists 58–59 D-Index: 129 scientists 60–61 D-Index: 120 scientists 62–63 D-Index: 105 scientists 64–65 D-Index: 131 scientists 66–67 D-Index: 95 scientists 68–69 D-Index: 97 scientists 70–71 D-Index: 106 scientists 72–73 D-Index: 83 scientists 74–75 D-Index: 89 scientists 76–77 D-Index: 77 scientists 78–79 D-Index: 70 scientists 80–81 D-Index: 73 scientists 82–83 D-Index: 60 scientists 84–85 D-Index: 48 scientists 86–87 D-Index: 45 scientists 88–89 D-Index: 50 scientists 90–91 D-Index: 31 scientists 92–93 D-Index: 51 scientists 94–95 D-Index: 43 scientists 96–97 D-Index: 38 scientists 98–99 D-Index: 39 scientists 100–101 D-Index: 41 scientists 102–103 D-Index: 29 scientists 104–105 D-Index: 33 scientists 106–107 D-Index: 35 scientists 108–109 D-Index: 20 scientists 110–111 D-Index: 38 scientists 112–113 D-Index: 19 scientists 114–115 D-Index: 28 scientists 116–117 D-Index: 13 scientists 118–119 D-Index: 23 scientists 120–121 D-Index: 16 scientists 122–123 D-Index: 15 scientists 124–125 D-Index: 11 scientists 126–127 D-Index: 21 scientists 128–129 D-Index: 7 scientists 130–131 D-Index: 13 scientists 132–133 D-Index: 14 scientists 134–135 D-Index: 17 scientists 136–137 D-Index: 9 scientists 138–139 D-Index: 8 scientists 140–141 D-Index: 16 scientists 142–143 D-Index: 7 scientists 144 D-Index: 7 scientists 145+ D-Index: 100 scientists
40 D-Index 145+

This scientist: 87 D-Index — 74th percentile

74% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 145 D-Index or more.

Overview

Akira Nakagawara is affiliated with the Saga Group in the United Kingdom and has contributed extensively to research in medicine and molecular biology. Their work primarily focuses on neuroblastoma research and treatments, with a significant emphasis on cancer therapeutics and the mechanisms underlying cancer development and progression.

The scientist's research spans multiple interconnected fields, including medicine, biochemistry, genetics, and molecular biology. Specific subfields of study they have contributed to include neurology, molecular biology, cell biology, oncology, and cancer research. Their publications explore complex biological processes and pathways relevant to cancer and neurological disorders.

Frequent publication venues for the scientist include the Japanese Journal of Clinical Oncology, Biomolecules, Frontiers in Oncology, Cells, and the International Journal of Clinical Oncology. These journals reflect the biomedical focus and clinical relevance of their research.

Notable recent papers authored or co-authored by Nakagawara include:

  • De novo evolved gene product NCYM in the pathogenesis and clinical outcome of human neuroblastomas and other cancers (2020, Japanese Journal of Clinical Oncology)
  • UNC5 dependence receptor family in human cancer: A controllable double-edged sword (2021, Cancer Letters)
  • Retrospective Analysis of INRG Clinical and Genomic Factors for 605 Neuroblastomas in Japan: A Report from the Japan Children's Cancer Group Neuroblastoma Committee (JCCG-JNBSG) (2021, Biomolecules)
  • The Role of MYCN in Symmetric vs. Asymmetric Cell Division of Human Neuroblastoma Cells (2020, Frontiers in Oncology)
  • Acceleration or Brakes: Which Is Rational for Cell Cycle-Targeting Neuroblastoma Therapy? (2021, Biomolecules)

Frequent collaborators in Nakagawara's research efforts include Kimikazu Matsumoto, Hideki Izumi, Tetsuya Takimoto, Tomoro Hishiki, and Hiroyuki Shichino. These co-authors have been involved in multiple joint publications, indicating longstanding research partnerships.

The main topics covered by Nakagawara's work emphasize neuroblastoma research and treatments, cancer therapeutics and mechanisms, as well as cancer, hypoxia, and metabolism. Additional areas of focus include signaling pathways in disease, Hippo pathway signaling and YAP/TAZ, lung cancer research studies, and zebrafish biomedical research applications.

Best Publications

  • Oncogenic mutations of ALK kinase in neuroblastoma.

    Yuyan Chen;Junko Takita;Young Lim Choi;Motohiro Kato

  • Advances in Risk Classification and Treatment Strategies for Neuroblastoma

    Navin R. Pinto;Mark A. Applebaum;Samuel L. Volchenboum;Katherine K. Matthay

  • Cloning and functional analysis of human p51, which structurally and functionally resembles p53

    Motonobu Osada;Mai Ohba;Chikashi Kawahara;Chikashi Ishioka

  • Role of p53 in Cell Death and Human Cancers

    Toshinori Ozaki;Akira Nakagawara

  • Trk receptor tyrosine kinases: A bridge between cancer and neural development

    Akira Nakagawara

  • High expression of Survivin, mapped to 17q25, is significantly associated with poor prognostic factors and promotes cell survival in human neuroblastoma.

    Ashraful Islam;Hajime Kageyama;Naoyuki Takada;Takemasa Kawamato

  • International consensus for neuroblastoma molecular diagnostics: report from the International Neuroblastoma Risk Group (INRG) Biology Committee.

    PF Ambros;IM Ambros;GM Brodeur;M Haber

  • Hydrogen peroxide metabolism in human monocytes during differentiation in vitro.

    A Nakagawara;C F Nathan;Z A Cohn

  • Activation of AMP-activated Protein Kinase Induces p53-dependent Apoptotic Cell Death in Response to Energetic Stress

    Rintaro Okoshi;Toshinori Ozaki;Hideki Yamamoto;Kiyohiro Ando

  • A New Family of Heparin-binding Growth/Differentiation Factors: Increased Midkine Expression in Wilms' Tumor and Other Human Carcinomas

    Jun-ichiro Tsutsui;Kenji Kadomatsu;Shyuichiro Matsubara;Akira Nakagawara

  • Polo-like kinase 1 (Plk1) inhibits p53 function by physical interaction and phosphorylation.

    Kiyohiro Ando;Toshinori Ozaki;Hideki Yamamoto;Kazushige Furuya

  • Meta-analysis of Neuroblastomas Reveals a Skewed ALK Mutation Spectrum in Tumors with MYCN Amplification

    Sara De Brouwer;Katleen De Preter;Candy Kumps;Piotr Zabrocki

  • Clinical and Biologic Features Predictive of Survival After Relapse of Neuroblastoma: A Report From the International Neuroblastoma Risk Group Project

    Wendy B. London;Victoria Castel;Tom Monclair;Peter F. Ambros

  • PPM1D is a potential target for 17q gain in neuroblastoma

    Fumiko Saito-Ohara;Issei Imoto;Jun Inoue;Hajime Hosoi

  • HMGB1 and HMGB2 cell-specifically down-regulate the p53- and p73-dependent sequence-specific transactivation from the human Bax gene promoter.

    Michal Štros;Toshinori Ozaki;Alena Bačı́ková;Hajime Kageyama

  • Autoinhibitory Regulation of p73 by ΔNp73 To Modulate Cell Survival and Death through a p73-Specific Target Element within the ΔNp73 Promoter

    Takahito Nakagawa;Masato Takahashi;Toshinori Ozaki;Ken-ichi Watanabe

  • UbcH10 Is the Cancer-related E2 Ubiquitin-conjugating Enzyme

    Yoshiaki Okamoto;Toshinori Ozaki;Kou Miyazaki;Mineyoshi Aoyama

  • CpG Island Methylator Phenotype Is a Strong Determinant of Poor Prognosis in Neuroblastomas

    Masanobu Abe;Miki Ohira;Atsushi Kaneda;Yukiko Yagi

  • Targeting a Complex Transcriptome: The Construction of the Mouse Full-Length cDNA Encyclopedia

    Piero Carninci;Kazunori Waki;Toshiyuki Shiraki;Hideaki Konno

  • NEDL1, a novel ubiquitin-protein isopeptide ligase for dishevelled-1, targets mutant superoxide dismutase-1.

    Kou Miyazaki;Tomoyuki Fujita;Toshinori Ozaki;Chiaki Kato

Frequent Co-Authors

Satoru Todo
Satoru Todo Hokkaido University
Wendy B. London
Wendy B. London Harvard University
Naohiko Seki
Naohiko Seki Chiba University
Peter F. Ambros
Peter F. Ambros St Anna Children's Hospital
Katherine K. Matthay
Katherine K. Matthay University of California, San Francisco
Hideki Yamamoto
Hideki Yamamoto Osaka University
Susan L. Cohn
Susan L. Cohn University of Chicago
Yasuhiko Kaneko
Yasuhiko Kaneko Saitama Cancer Center
John M. Maris
John M. Maris Children's Hospital of Philadelphia
Garrett M. Brodeur
Garrett M. Brodeur Children's Hospital of Philadelphia

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For students interested in Molecular Biology careers, there are multiple online degree options to consider. Many professionals start by completing their RN to BSN or similar undergraduate degrees. When comparing programs, resources like capella university vs wgu rn to bsn can help you analyze flexible study formats, tuition rates, and graduate outcomes.

Pursuing advancement, such as a master's degree, is also possible online. Those seeking cost-effective options can explore the cheapest bsn to msn online programs, which make further specialization and career mobility more accessible.

Accreditation and reputation matter when choosing an online program. Looking for a non profit university often ensures higher education standards and student support. Additionally, if you are a current or former service member, selecting one of the veteran friendly online colleges can provide benefits such as tuition assistance, flexible scheduling, and dedicated military support services.

With the right degree pathway, graduates can open doors to rewarding roles in research, clinical practice, healthcare leadership, or biotechnology.

Best Scientists Citing Akira Nakagawara

Trending Scientists

Recently Published Articles